Allosteric Bioscience, Inc , a company founded in 2021 to integrate Quantum Computing and Artificial Intelligence with various Biomedical sciences to create improved treatments for Aging, Longevity and Aging related diseases, has partnered with POLARISqb to research protein targets that may play a key role in human aging.
Improved Aging, Longevity and Aging related diseases is a lead program at Allosteric Bioscience and the focus of this new agreement. This agreement is also supported by an equity investment in Polarisqb. This agreement initiates a joint program involves using Quantum Computing and advanced artificial intelligence (AI) technology for creation of an inhibitor of a key protein involved in human Aging and Longevity. This program’s goal is to significantly improve the normal human Aging and Longevity process which could have benefits for global health that represents a multibillion-dollar global market. Allosteric Bioscience believes that the power of Quantum Computing and advanced AI are a powerful combination for the creation of pharmaceuticals targeting toxic pathways which have been difficult to generate in the past.